367 related articles for article (PubMed ID: 33569063)
1. B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies.
Willsmore ZN; Harris RJ; Crescioli S; Hussein K; Kakkassery H; Thapa D; Cheung A; Chauhan J; Bax HJ; Chenoweth A; Laddach R; Osborn G; McCraw A; Hoffmann RM; Nakamura M; Geh JL; MacKenzie-Ross A; Healy C; Tsoka S; Spicer JF; Papa S; Barber L; Lacy KE; Karagiannis SN
Front Immunol; 2020; 11():622442. PubMed ID: 33569063
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy.
Plesca I; Tunger A; Müller L; Wehner R; Lai X; Grimm MO; Rutella S; Bachmann M; Schmitz M
Front Immunol; 2020; 11():364. PubMed ID: 32194568
[TBL] [Abstract][Full Text] [Related]
3. Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma.
Maibach F; Sadozai H; Seyed Jafari SM; Hunger RE; Schenk M
Front Immunol; 2020; 11():2105. PubMed ID: 33013886
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma.
Lynch KT; Young SJ; Meneveau MO; Wages NA; Engelhard VH; Slingluff CL; Mauldin IS
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34103353
[TBL] [Abstract][Full Text] [Related]
5. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.
Andersen R; Borch TH; Draghi A; Gokuldass A; Rana MAH; Pedersen M; Nielsen M; Kongsted P; Kjeldsen JW; Westergaard MCW; Radic HD; Chamberlain CA; Hölmich LR; Hendel HW; Larsen MS; Met Ö; Svane IM; Donia M
Ann Oncol; 2018 Jul; 29(7):1575-1581. PubMed ID: 29688262
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients.
Pirozyan MR; McGuire HM; Emran AA; Tseng HY; Tiffen JC; Lee JH; Carlino MS; Menzies AM; Long GV; Scolyer RA; Fazekas de St Groth B; Hersey P
Front Immunol; 2020; 11():372. PubMed ID: 32210968
[TBL] [Abstract][Full Text] [Related]
7. A B-cell or a key player? The different roles of B-cells and antibodies in melanoma.
Rodgers CB; Mustard CJ; McLean RT; Hutchison S; Pritchard AL
Pigment Cell Melanoma Res; 2022 May; 35(3):303-319. PubMed ID: 35218154
[TBL] [Abstract][Full Text] [Related]
8. Tertiary lymphoid structures improve immunotherapy and survival in melanoma.
Cabrita R; Lauss M; Sanna A; Donia M; Skaarup Larsen M; Mitra S; Johansson I; Phung B; Harbst K; Vallon-Christersson J; van Schoiack A; Lövgren K; Warren S; Jirström K; Olsson H; Pietras K; Ingvar C; Isaksson K; Schadendorf D; Schmidt H; Bastholt L; Carneiro A; Wargo JA; Svane IM; Jönsson G
Nature; 2020 Jan; 577(7791):561-565. PubMed ID: 31942071
[TBL] [Abstract][Full Text] [Related]
9. B cells and tertiary lymphoid structures promote immunotherapy response.
Helmink BA; Reddy SM; Gao J; Zhang S; Basar R; Thakur R; Yizhak K; Sade-Feldman M; Blando J; Han G; Gopalakrishnan V; Xi Y; Zhao H; Amaria RN; Tawbi HA; Cogdill AP; Liu W; LeBleu VS; Kugeratski FG; Patel S; Davies MA; Hwu P; Lee JE; Gershenwald JE; Lucci A; Arora R; Woodman S; Keung EZ; Gaudreau PO; Reuben A; Spencer CN; Burton EM; Haydu LE; Lazar AJ; Zapassodi R; Hudgens CW; Ledesma DA; Ong S; Bailey M; Warren S; Rao D; Krijgsman O; Rozeman EA; Peeper D; Blank CU; Schumacher TN; Butterfield LH; Zelazowska MA; McBride KM; Kalluri R; Allison J; Petitprez F; Fridman WH; Sautès-Fridman C; Hacohen N; Rezvani K; Sharma P; Tetzlaff MT; Wang L; Wargo JA
Nature; 2020 Jan; 577(7791):549-555. PubMed ID: 31942075
[TBL] [Abstract][Full Text] [Related]
10. B Cell Orchestration of Anti-tumor Immune Responses: A Matter of Cell Localization and Communication.
Kinker GS; Vitiello GAF; Ferreira WAS; Chaves AS; Cordeiro de Lima VC; Medina TDS
Front Cell Dev Biol; 2021; 9():678127. PubMed ID: 34164398
[TBL] [Abstract][Full Text] [Related]
11. Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients.
Carbone ML; Madonna G; Capone A; Bove M; Mastroeni S; Levati L; Capone M; Ascierto PA; De Galitiis F; D'Atri S; Fortes C; Volpe E; Failla CM
Sci Rep; 2022 Mar; 12(1):5448. PubMed ID: 35361879
[TBL] [Abstract][Full Text] [Related]
12. Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma.
Borch TH; Andersen R; Ellebaek E; Met Ö; Donia M; Svane IM
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32747469
[TBL] [Abstract][Full Text] [Related]
13. Correlative Monitoring of Immune Activation and Tissue Damage in Malignant Melanoma-An Algorithm for Identification of Tolerance Breakage During Immune Checkpoint Inhibitor Therapy of Cancer.
Wahl RU; Leijs M; Araujo A; Rübben A
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32188047
[TBL] [Abstract][Full Text] [Related]
14. The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell-Mediated Immunotherapies.
Varghese S; Pramanik S; Williams LJ; Hodges HR; Hudgens CW; Fischer GM; Luo CK; Knighton B; Tan L; Lorenzi PL; Mackinnon AL; McQuade JL; Hailemichael Y; Roszik J; Peng W; Vashisht Gopal YN
Mol Cancer Ther; 2021 Mar; 20(3):500-511. PubMed ID: 33361272
[TBL] [Abstract][Full Text] [Related]
15. Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma.
Saito R; Sawada Y; Nakamura M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669410
[TBL] [Abstract][Full Text] [Related]
16. Role of immune checkpoint inhibitors in the revolutionization of advanced melanoma care.
Singh S; Numan A; Agrawal N; Tambuwala MM; Singh V; Kesharwani P
Int Immunopharmacol; 2020 Jun; 83():106417. PubMed ID: 32200155
[TBL] [Abstract][Full Text] [Related]
17. Tumor fitness, immune exhaustion and clinical outcomes: impact of immune checkpoint inhibitors.
Bubie A; Gonzalez-Kozlova E; Akers N; Villanueva A; Losic B
Sci Rep; 2020 Mar; 10(1):5062. PubMed ID: 32193450
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Biomarkers for Melanoma Immunotherapy.
Twitty CG; Huppert LA; Daud AI
Curr Oncol Rep; 2020 Feb; 22(3):25. PubMed ID: 32048065
[TBL] [Abstract][Full Text] [Related]
19. Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma: a short report.
de Joode K; Veenbergen S; Kransse C; Kortleve D; Debets R; Mathijssen RHJ; Joosse A; Schreurs MWJ; Van der Veldt AAM
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36750254
[TBL] [Abstract][Full Text] [Related]
20. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
Front Immunol; 2020; 11():784. PubMed ID: 32457745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]